Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 11;527(2):126-31.
doi: 10.1016/j.neulet.2012.08.051. Epub 2012 Sep 5.

cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons

Natura Myeku  1 , Hu Wang, Maria E Figueiredo-Pereira
Affiliations

cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons

Natura Myeku et al. Neurosci Lett. .

Abstract

Proteasome impairment and accumulation of ubiquitinated proteins are implicated in neurodegeneration associated with different forms of spinal cord injury. We show herein that elevating cAMP in rat spinal cord neurons increases 26S proteasome activity in a protein kinase A-dependent manner. Treating spinal cord neurons with dibutyryl-cAMP (db-cAMP) also raised the levels of various components of the UPP including proteasome subunits Rpt6 and β5, polyubiquitin shuttling factor p62/sequestosome1, E3 ligase CHIP, AAA-ATPase p97 and the ubiquitin gene ubB. Finally, db-cAMP reduced the accumulation of ubiquitinated proteins, proteasome inhibition, and neurotoxicity triggered by the endogenous product of inflammation prostaglandin J2. We propose that optimizing the effects of cAMP/PKA-signaling on the UPP could offer an effective therapeutic approach to prevent UPP-related proteotoxicity in spinal cord neurons.

PubMed Disclaimer

Conflict of interest statement

Competing interests

None.

Figures

Figure 1
Figure 1. Elevating cAMP stimulates the 26S proteasome via PKA
Rat E18 spinal cord neurons were treated for 24h with: (A) 0.5% DMSO (control), 1 mM db-cAMP, or 100 μM forskolin/10 μM rolipram (Fk+Rlp); (B) 0.5% DMSO (control), pretreated for one hour with 100 μM Rp-cAMPS followed by 1 mM db-cAMP (Rp-cAMPS + Db-cAMP), or 1 mM db-cAMP. Clear lysates (80 μg/sample) were subjected to non-denaturing gel electrophoresis. Proteasomal chymotrypsin-like activity was assessed with Suc-LLVY-AMC by the in-gel assay (left panels). 26S and 20S proteasome levels (indicated by arrows) were detected by immunoblotting with anti-Rpt6 and anti-β5 (middle and right panels). βIII-Tubulin (loading control). Activity and immunoblot bands were semi-quantified by densitometry. Percentages represent the ratio between data for each condition and control (DMSO) considered to be 100%. Values indicate means from at least three experiments. Asterisks identify values that are significantly different from control (*p <0.05; **p<0.01; ***p<0.001).
Figure 2
Figure 2. Effect of elevating cAMP on components of the UPP
Rat E18 spinal cord neurons were treated with 0.5% DMSO (control), 1 mM db-cAMP, or 100 μM forskolin/10 μM rolipram (Fk+Rlp) for 24h. Western blot analyses (40 μg of protein/lane; 10% gels) detected in: (A) proteasome subunits (Rpt6 and β5), p62/sqstm1, and PKA catalytic subunit Cα (PKA sub Cα); (B) CHIP, p97/VCP, Parkin, and p47/Ubx1; βIII-tubulin in A and B (loading control). Molecular mass markers in kDa are on the left. (C) Expression of the listed genes (normalized to gapdh) by quantitative RT-PCR. Percentages represent the ratio between the relative intensities for each condition and control (DMSO) considered to be 100%. (D) PKA activity determined with a nonradioactive assay kit. Values indicate means (and S.E. in C and D) from at least three experiments. Asterisks identify values that are significantly different from control (*p <0.05; **p<0.01; ***p<0.001).
Figure 3
Figure 3. Elevating cAMP diminishes (A) accumulation of ubiquitinated proteins, (B) 26S proteasome inhibition, (C) loss of cell viability, and (D) cytotoxicity induced by PGJ2
Rat E18 spinal cord neurons were treated separately with 0.5% DMSO (control), 1 mM db-cAMP, 100 μM forskolin/10 μM rolipram (Fk+Rlp) or 20 μM PGJ2 for 24h. Parallel cultures were pretreated for one hour with 1 mM db-cAMP or 100 μM forskolin/10 μM rolipram (Fk+Rlp) followed by 20 μM PGJ2 for 24h (Db-cAMP+J2 or Fk+Rlp+J2). (A) Western blot analysis (40 μg of protein/lane; 10% gels) detecting ubiquitinated proteins (Ub-proteins) and βIII-tubulin (loading control). (B) Proteasomal chymotrypsin-like activity (left panel) and levels (middle and right panels) were assessed as described in Fig. 1. 26S and 20S proteasomes are indicated by arrows. βIII-Tubulin (loading control). (C) Cell viability measured with the MTT assay. In A, B and C percentages represent the ratio between the data for each condition and control (DMSO) considered to be 100%. (D) Cell toxicity was assessed with the bioluminescent cytotoxicity assay and expressed as RU (relative units). Values indicate means and S.E. from at least three experiments. Asterisks identify values that are significantly different from control (*p <0.05; **p<0.01; ***p<0.001). Furthermore, in (A) there is no significant difference between control and db-cAMP or Fk+Rlp within the DMSO- or J2-treatment groups. In (C) and (D) there is no significant difference between control and db-cAMP or Fk+Rlp within the DMSO-treatment group. Within the J2-treatment group, J2 alone is significantly different (p<0.001) from J2+db-cAMP or J2+(Fk+Rlp).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahlgren S, Li GL, Olsson Y. Accumulation of beta-amyloid precursor protein and ubiquitin in axons after spinal cord trauma in humans: immunohistochemical observations on autopsy material. Acta Neuropathol. 1996;92:49–55. - PubMed
    1. Asai M, Tsukamoto O, Minamino T, Asanuma H, Fujita M, Asano Y, Takahama H, Sasaki H, Higo S, Asakura M, Takashima S, Hori M, Kitakaze M. PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol. 2009;46:452–462. - PubMed
    1. Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res. 1993;35:567–576. - PubMed
    1. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723–749. - PubMed
    1. Costa J, Gomes C, de CM. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets. 2010;9:764–778. - PubMed

Publication types

LinkOut - more resources